Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J

Cardiovasc Pharmacol. 1998;32 (Suppl 3):S22–S28.

Maisel AS et al. Rapid measurement of the B-type natriuretic peptide in the emergency diagnosis of heart failure.

N EnglJ Med. 2002;347(3):161–167.

Lee CR et al. Surrogate endpoints in heart failure. Ann Pharmacother. 2002;36(3):479–488.

Troughton et al. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP)

concentrations. Lancet. 2000;355(9210):1126–1130.

Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic

emergency department patient. Rev Cardiovasc Med. 2002;3(Suppl 4):S10–S17.

Vichiendilokkul et al. Nesiritide: a novel approach for acute heart failure. Ann Pharmacother. 2003;37(2):247–

258.

Colucci WS et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated heart failure. N

EnglJ Med. 2000;343(4):246–253.

Gheorghiade M et al. Effects of tolvaptan a vasopressin antagonist, in patient hospitalized with worsening heart

failure. JAMA. 2004;291(16):1963.

Gheorghiade M et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist in patients

hospitalized for heart failure. The EVEREST Clinical Trials. JAMA. 2007;297(12):1332–1343.

Konstam MA et al. Effects of oral tolvaptan in patient hospitalized with worsening heart failure. JAMA.

2007;297(12):1319–1331.

Earl GL, Fitzpatrick JT. Levosimendan: a novel inotropic agent for treatment of acute decompensated heart

failure. Ann Pharmacother. 2005;39(11):1888–1896.

Follath F et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low output

heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002;360(9328):196–202.

Moiseyev et al. Safety and efficacy of novel calcium sensitizer, levosimendan, in patients with left ventricular

failure due to an acute myocardial infarction. Eur Heart J. 2002;23(18):1422–1432.

Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely

decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions

2005; November 13–16, 2005; Dallas, Texas. Late Breaking Clinical Trials II. Circulation 2005;112:3363.

Mebazaa A et al. The SURVIVE Randomized Trial: levosimendan vs dobutamine for patients with acute

decompensated heart failure. JAMA. 2007;297(17):1883–1891.

Shan K et al. The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 1997;12(3):218–223.

Kapadia S et al. The role of cytokines in the failing human heart. Cardiol Clin. 1998;16(4):645–656.

Mabuchi N et al. Relationship between interleukin-6 production in the lungs and pulmonary vascular resistance in

patients with congestive heart failure. Chest. 2002;121(4):1195–1202.

Bolger A, Anker S. Tumour necrosis factor in chronic heart failure. Drugs. 2000;60(6):1245–1257.

Herrera-Garza E et al. Tumor necrosis factor: a mediator of disease progression in the failing human heart.

Chest. 1999;115:1170.

Bozkurt B et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with

advanced heart failure. Circulation. 2001;103(8):1044–1047.

Kwon HJ et al. Case reports of heart failure after therapy with tumor necrosis factor antagonist. Ann Intern

Med. 2003;138(10):807–811.

Vanhoutte PM et al. Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol.

1995;76(15):3E–12E.

Sueta CA et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J

Cardiol. 1995;75(3):34A–43A.

Califf RM et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the

Flolan international randomized survival trial (FIRST). Am Heart J. 1997;134(1):44–54.

O’ConnellJB, Bristow M. The economic burden of heart failure. Clin Cardiol. 2000;23(Suppl III):III6–III10.

Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction.

JAMA. 1994;271(16):1276–1280.

Vasan R et al. Congestive heart failure with normal left ventricular systolic function: clinical approach to the

diagnosis and treatment of diastolic heart failure. Arch Intern Med. 1996;156(2):146–157.

Garcia M. Diastolic dysfunction and heart failure: causes and treatment options. Cleve Clin J Med.

2000;67(10):727–729.

Flynn KE et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION

randomized controlled trial. JAMA. 2009;301(14):1451–1459.

Son YJ et al. Adherence to a sodium-restricted diet is associated with lower symptom burden and longer cardiac

event-free survival in patients with heart failure. J Clin Nurs. 2011;20(21/22):3029–3038.

Arcand J et al. A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart

failure patients: a prospective follow-up study. Am J Clin Nutr. 2011;93(2):332–337.

DiNicolantonio JJ et al. Low sodium versus normal sodium diets in systolic heart failure: systematic review and

meta-analysis. Heart (Br Card Soc). 2012. doi:10.1136/heartjnl-2012-302337.

Aliti GB et al. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical

trial. JAMA Intern Med. 2013;173(12):1058–1064.

Bentley B et al. Factors related to nonadherence to low sodium diet recommendations in heart failure patients.

Eur J Cardiovasc Nurs. 2005;4(4):331–336.

Neily JB et al. Potential contributing factors to noncompliance with dietary sodium restriction in patients with

heart failure. Am Heart J. 2002;143(1):29–33.

Brater DC. Pharmacology of diuretics. Am J Med Sci. 2000;319(1):38–50.

Krämer B et al. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106(1):90–96.

Pitt B et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N EnglJ

Med. 1999;341(10):709–717.

Pitt B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after

myocardial infarction. N EnglJ Med. 2003;348(14):1309–1321.

Rodgers J, Patterson JH. The role of the renin-angiotensin-aldosterone system in the management of heart

failure. Pharmacotherapy. 2002;20(11, Pt 2):368S–378S.

Patterson JH. Angiotensin II receptor blockers in heart failure. Pharmacotherapy. 2003;23(2):173–182.

van Veldhuisen DJ et al. Value of digoxin in heart failure and sinus rhythm: new features of an old drug. J Am

Coll Cardiol. 1996;28(4):813–819.

van Veldhuisen D et al. Progression of mild untreated heart failure during 6 months follow-up and clinical and

neurohumoral effects of ibopamine and digoxin as monotherapy. Am J Cardiol. 1995;75(12):796–800.

Cohn JN et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med.

1986;314(24):1547–1552.

Taylor AL et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med.

2004;351(20):2049–2057.

Packer M et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective

Randomized Amlodipine Survival Evaluation Study Group. N EnglJ Med. 1996;335(15):1107–1114.

Cohn JN et al. Effect of the calcium antagonist felodipine as supplemental vasodilator therapy in patients with

chronic heart failure treated with enalapril. V-HeFT III. Circulation. 1997;96(3):856–863.

Linde C et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in

asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol.

2008;52(23):1834–1843.

Moss AJ et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med.

2009;361(14):1329–1338.

Cleland JG et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J

Med. 2005;352(15):1539–1549.

Bristow MR et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced

chronic heart failure. N EnglJ Med. 2004;350(21):2140–2150.

Rose EA et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med.

2001;345(20):1435–1443.

Miller LW et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med.

2007;357(9):885–896.

Slaughter MS et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J

Med. 2009;361(23):2241–2251.

Aaronson K. Evaluation of the HeartWare® HVAD Left Ventricular Assist Device Systemfor the Treatment of

Advanced Heart Failure: Results of the ADVANCE Bridge to Transplant Trial. American Heart Association

2010 Scientific Sessions.Late-Breaking Clinical Trials I; November 14, 2010; Chicago, IL. Clin Res Cardiol.

2011;100:2.

Gullestad L et al. What resting heart rate should one aim for when treating patients with heart failure with a betablocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial

in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2005;45(2):252–259.

Lechat P et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in

CIBIS II Trial. Circulation. 2001;103(10):1428–1433.

Castagno D et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart

failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and

morbidity) program. J Am Coll Cardiol. 2012;59(20):1785–1795.

Flannery G et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on

clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol.

2008;101(6):865–869.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

Swedberg K et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled

study. Lancet. 2010;376(9744):875–885.

McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med.

2014;371(11):993–1004.

McMurray JJ et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting

enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective

comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial

(PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062–1073.

Schocken DD et al. Prevention of heart failure: a scientific statement from the American Heart Association

Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood

Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional

Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117(19):2544–2565.

de Couto G et al. Early detection of myocardial dysfunction and heart failure. Nat Rev. 2010;7(6):334–344.

Roger VL et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association.

Circulation. 2011;123:e18.

Huerta C et al. Non-steroidal anti-inflammatory drugs and risk of first hospitalization admissions for heart failure

in the general population. Heart (Br Card Soc). 2006;92(11):1610–1615.

Heerdink ER et al. NSAIDS associated with increased risk of congestive heart failure in elderly patients taking

diuretics. Arch Intern Med. 1998;158(10):1108–1112.

Page J, Henry D. Consumption of NSAIDS and the development of congestive heart failure in elderly patients: an

under-recognized public health problem. Arch Intern Med. 2000;160(6):777–784.

Shan K et al. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125(1):47–58.

Singal P, Iliskovic N. Doxorubicin-induced cardiomyopathy. N EnglJ Med. 1998;339:900.

Page RL et al. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.

Pharmacotherapy. 2003;23(7):945–954.

Scirica BM et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N EnglJ Med.

2013;369(14):1317–1326.

Hunt SA et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and

Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American

Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society

for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–e479.

Risler T et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure.

Cardiology. 1994;84(Suppl 2):155–161.

Murray MD et al. Torsemide more effective that furosemide for treatment of heart failure. Am J Med.

2001;111(7):513–520.

Cutler R, Blair A. Clinical pharmacokinetics of furosemide. Clin Pharmacokinet. 1979;4(4):279–296.

Greither A et al. Pharmacokinetics of furosemide in patients with congestive heart failure. Pharmacology.

1979;19(3):121–131.

Straughn AB et al. Bioavailability of seven furosemide tablets in man. Biopharm Drug Dispos. 1986;7(2):113–

120.

McNamara PJ et al. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study. Pharm

Res. 1987;4(2):150–153.

Vargo DL et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in

patients with congestive heart failure. Clin Pharmacol Therap. 1995;57(6):601–609.

Rudy DW et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than

bolus therapy. Ann Intern Med. 1991;115(5):360–366.

Van Meyel J et al. Continuous infusion of furosemide in the treatment of patients with congestive heart failure

and diuretic resistance. J Intern Med. 1994;235:329.

Thomson MR et al. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure.

J Card Fail. 2010;16(3):188–193.

Felker GM et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med.

2011;364(9):797–805.

Haley H, Ploth DW. Dyshomeostasis of serum sodium concentration in congestive heart failure. Am J Med Sci.

2010;340(1):42–47.

Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalemia and potassium loss during maintenance

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

digoxin therapy. Br Heart J. 1976;38(2):167–172.

Holland OB et al. Diuretic-induced ventricular ectopic activity. Am J Med. 1981;770(4):762–768.

Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia and cardiac arrhythmias. Acta Med Scand Suppl.

1981;647:67–73.

Tsuji H et al. The association of levels of serum potassium and magnesium with ventricular premature

complexes (the Framingham Heart Study). Am J Cardiol. 1994;74(3):237–235.

Cohn JN et al. New guidelines for potassium replacement in clinical practice. Arch Intern Med.

2000;160(16):2429–2436.

Hollifield JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med.

1984;77(5A):28–32.

Anker SD et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional,

and hemodynamic staging. Circulation. 2003;107(15):1991–1997.

Felker GM et al. Natriuretic peptides in the diagnosis and management of heart Failure. Can Med Assoc J.

2006;175(6):611–617.

Jourdain P et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the

STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49(16):1733–1739.

Lainchbury JG et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the

“BATTLESCARRED” trial. Eur J Heart Fail. 2006;8(5):532–538.

Pfisterer M et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard

Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA.

2009;301(4):383–392.

Felker GM et al. Effect of Natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in

high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trialJAMA.

2017;318(8):713–720. doi:10.1001/jama.2017.10565

Kosman ME. Management of potassium problems during long-term diuretic therapy. JAMA. 1974;230(5):743–

748.

Davidson C et al. Effect of long-term diuretic treatment on body potassium in heart disease. Lancet.

1976;2(2):1044–1047.

Schwartz AB, Swartz CD. Dosage of potassium chloride elixir to correct thiazide-induced hypokalemia. JAMA.

1974;230(5):702–704.

Lahav M et al. Continuous infusion furosemide in patients with severe CHF. Chest. 1992;102(3):725–731.

Dormans T et al. Diuretic efficacy of high-dose furosemide in severe heart failure: bolus injections versus

continuous infusion. J Am Coll Cardiol. 1996;28:376.

Kramer WG et al. Pharmacodynamics of torsemide as an intravenous injection and as a continuous infusion to

patients with congestive heart failure. J Clin Pharmacol. 1996;36(3):26–70.

Sica D, Gehr TW. Diuretic combinations in refractory edema states. Clin Pharmacokinet. 1996;30:229–249.

Howard P, Dunn M. Aggressive diuresis is safe and cost effective for severe heart failure in the elderly. Chest.

2001;119(3):807–810.

Rosenberg J et al. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart

failure: an observationalstudy and review of the literature. Cardiovasc Drugs Ther. 2005;19(4):301–306.

Wollert KC, Drexler H. The kallikreins-kinin system in post myocardial infarction cardiac remodeling. Am J

Cardiol. 1997;80(3A):158A–161A.

White CM. Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction. Am J Health

Syst Pharm. 2000;57(Suppl 1):S18–S25.

Garg R, Yusuf S. Overview of randomized trials on angiotensin-converting enzyme inhibition on mortality and

morbidity in patients with heart failure. JAMA. 1995;273(18):1450–1456.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection

fractions and congestive heart failure. N EnglJ Med. 1991;325(5):295–302.

Zannad F et al. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart

failure. Fosinopril in Heart Failure Study Investigators. Am Heart J. 1998;136(4, Pt 1):672–680.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure.

Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med.

1987;316(23):1429–1435.

Kjekshus J et al. Effects of enalapril on long-term mortality in severe congestive heart failure. Am J Cardiol.

1992;69(1):103–107.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

Cohn JN et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic

congestive heart failure. N EnglJ Med. 1991;325(5):303–310.

Hobbs RE. Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure? Cleve Clin J

Med. 1998;65(10):539–542.

Packer M et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor,

lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation.

1999;100(23):2312–2318.

The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose

comparison. Eur Heart J. 1998;19(3):481–489.

Martineau P, Goulet J. New competition in the realm of renin-angiotensin axis inhibition: the angiotensin II

receptor antagonists in congestive heart failure. Ann Pharmacother. 2001;35(1):71–84.

Jong P et al. Angiotensin receptor blockers in heart failure: a meta-analysis of randomized controlled trials. J Am

Coll Cardiol. 2002;39(3):463–470.

Riegger GA et al. Improvement in exercise tolerance and symptoms of congestive heart during treatment with

candesartan cilexetil. Circulation. 1999;100(22):2224–2230.

Havranek EP et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart

failure. J Am Coll Cardiol. 1999;33(5):1174–1181.

Dickstein K et al. Comparison of the effects of losartan and enalapril on clinical status and exercise

performance in patients with moderate to severe heart failure. J Am Coll Cardiol. 1995;26(2):438–445.

Pitt B et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet.

1997;349(9054):747–752.

Pitt B et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:

randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–1587.

McKelvie RS et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure:

randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD

Pilot Study Investigators. Circulation. 1999;100(10):1056–1064.

Cohn J, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N

EnglJ Med. 2001;345(23):1667–1675.

Solomon SD et al. The valsartan in acute myocardial infarction trial (VALIANT) investigators. Sudden death in

patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med.

2005;352(25):2581–2588.

Granger CB et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular

systolic function intolerant to ACEIs: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–776.

McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular

systolic function taking ACEIs: the CHARM-Added trial. Lancet. 2003;362(9368):767–771.

Yusuf S et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection

fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781.

Pfeffer MA et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the

CHARM-overall programme. Lancet. 2003;362(9386):759–766.

Konstam MA et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart

failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–1848.

Luque C, Ortiz M. Treatment of ACE inhibitor induced cough. Pharmacotherapy. 1999;19(7):804–810.

Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical

practice guidelines. Chest. 2006;129(1, Suppl):169S–173S.

Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin-converting enzyme inhibitors in

Chinese. Br J Clin Pharmacol. 1995;40(2):141–144.

Schepkens H et al. Life threatening hyperkalemia during combined therapy with angiotensin-converting enzyme

inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110(6):438–441.

Wrenger E et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of

44 cases. BMJ. 2003;327(7407):147–149.

Juurlink DN et al. Rates of hyperkalemia after publication of randomized aldactone evaluation study. N Engl J

Med. 2004;351(6):543–551.

Palmer BF. Managing hyperkalemia cause by inhibition of renin-angiotensin aldosterone system. N Engl J Med.

2004;35(6):585–592.

Shah KB et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive

167.

168.

169.

170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

190.

191.

192.

193.

heart failure. J Am Coll Cardiol. 2005;46(5):845–849.

Vleeming W et al. ACE inhibitor-induced angioedema. Incidence, prevention, and management. Drug Saf.

1998;18(3):171–188.

Brown NJ et al. Black Americans have an increased risk of angiotensin converting enzyme inhibitor associated

angioedema. Clin Pharmacol Ther. 1996;60(1):8–13.

Brown NJ et al. Recurrent angiotensin converting enzyme inhibitor associated angioedema. JAMA.

1997;278(3):832–833.

Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk for the same problem

with AT-1 receptor blockade? Arch Intern Med. 2003;163(2):240–241.

Abdi R et al. Angiotensin II receptor blocker-associated angioedema. On the heels of ACE inhibitor

angioedema. Pharmacotherapy. 2002;22(9):1173–1175.

Lo KS. Angioedema associated with candesartan. Pharmacotherapy. 2002;22(9):1176–1179.

van Rijnsoever EW et al. Angioneurotic edema attributed to the use of losartan. Arch Intern Med.

1998;158(18):2063–2065.

Frye C, Pettigrew T. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy.

1998;18(4):866–868.

Brophy JM et al. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med.

2001;134(7):550–560.

Doughty RN et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic

overview of randomized controlled trials. Eur Heart J. 1997;18(4):560–565.

Avezum A et al. Beta-blocker therapy for congestive heart failure. Can J Cardiol. 1998;14(8):1045–1053.

Lechat P et al. Clinical effects of beta-adrenergic blockade in chronic heart failure. Circulation.

1998;98(12):1184–1191.

Heidenreich PA et al. Effects of beta-blockade on mortality in patients with heart failure. J Am Coll Cardiol.

1997;30(1):27–34.

Gattis WA et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure:

results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart

Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43(9):1534–1541.

Swedberg K et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary

(update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European

Society of Cardiology Eur Heart J. 2005;26(11):1115–1140.

Gattis W. Metoprolol CR/XL in the treatment of chronic heart failure. Pharmacotherapy. 2001;21(5):604–613.

Tangeman H, Patterson JH. Extended-release metoprololsuccinate in chronic heart failure. Ann Pharmacother.

2003;37(5):701–710.

Waagstein F et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated

Cardiomyopathy (MDC) Trial Study Group Lancet. 1993;342(8885):1441–1446.

Merit HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized

intervention trial in congestive heart failure (MERIT HF). Lancet. 1999;353:2001–2007.

CIBIS Investigators and Committees. A randomized trial of b-blockade in heart failure: the cardiac insufficiency

bisoprololstudy. Circulation. 1994;90:1765–1773.

Committees C-IIa. The cardiac insufficiency bisoprololstudy II: a randomized trial. Lancet. 1999;353:9–13.

Waagstein F et al. Long term beta-blockade in dilated cardiomyopathy: effects of short- and long-term

metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80(3):551–

563.

Bleske BE et al. Carvedilol: therapeutic application and practice guidelines. Pharmacotherapy. 1998;18(4):729–

737.

Packer M et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S.

Carvedilol Heart Failure Study Group. N EnglJ Med. 1996;334(21):1349–1355.

Bristow MR et al. Carvedilol produces dose-related improvements in left ventricular function and survival in

subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94(11):2807–2816.

Packer M et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to

severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and

Exercise Circulation. 1996;94(11):2793–2799.

Colucci WS et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US

Carvedilol Heart Failure Study Group Circulation. 1996;94(11):2800–2806.

194.

195.

196.

197.

198.

199.

200.

201.

202.

203.

204.

205.

206.

207.

208.

209.

210.

211.

212.

213.

214.

215.

216.

217.

218.

219.

220.

Cohn JN et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure

Study Group J Card Fail. 1997;3(3):173–179.

Greiner B et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest.

1999;104(2):147–153.

Meadowcroft AM et al. Pharmacogenetics and heart failure: a convergence with carvedilol. Pharmacotherapy.

1997;17(4):637–639.

Poole-Wilson PA et al. Comparison of carvedilol and metoprolol in clinical outcomes in patients with chronic

heart failure in the Carvedilol or Metoprolol European Trial (COMET). Lancet. 2003;362(9377):7–13.

Metra M et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized,

double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102(5):546–

551.

Packer M et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med.

2001;344(22):1651–1658.

Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with

advanced chronic heart failure. N EnglJ Med. 2001;344:1659.

Struthers AD. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart

failure? Br J Clin Pharmacol. 1999;47(5):479–482.

Jessup M. Aldosterone blockade and heart failure. N EnglJ Med. 2003;348(14):1380–1382.

Zannad F et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med.

2011;364(1):11–21.

Lee DC et al. Heart failure in outpatients. N EnglJ Med. 1982;306(12):699–705.

Jaeschke R et al. To what extent do congestive heart failure patients in normalsinus rhythm benefit from digoxin

therapy? A systematic overview and meta-analysis. Am J Med. 1990;88(3):279–286.

Kulick D, Rahimtoola S. Current role of digitalis therapy in patients with congestive heart failure. JAMA.

1991;265(22):2995–2997.

Uretsky BF et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate

chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll

Cardiol. 1993;26(4):93–62.

Packer M et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensinconverting-enzyme inhibitors. N EnglJ Med. 1993;329(1):17.

The Digitalis Intervention Group. The effect of digoxin on mortality and morbidity in patients with heart failure.

N EnglJ Med. 1997;336(8):525–533.

Adams KF Jr et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the

digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497–504.

Domanski M et al. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail.

2005;11(2):83–86.

Reuning R et al. Digoxin. Vancouver: Applied Therapeutics; 1992.

Bauer L. Digoxin. New York: McGraw Hill; 2001.

Matsuda M et al. Effects of digoxin, propranolol and verapamil on exercise in patients with chronic isolated atrial

fibrillation. Cardiovasc Res. 1991;25(6):453–457.

David D et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation:

beneficial effects of an added beta-adrenergic blocking agent. Am J Cardiol. 1979;44(7):1378–1382.

Farshi R et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise:

a crossover open-labelstudy of five drug regimens. J Am Coll Cardiol. 1999;33(2):304–310.

Deedwania PC et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with

heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of

antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators.

Circulation. 1998;98(23):2574–2579.

Pedersen OD et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left

ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.

Circulation. 2001;104(3):292–296.

Roy D et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med.

2008;358(25):2667–2677.

Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med.

2010;123(3):198–204.

221.

222.

223.

224.

225.

226.

227.

228.

229.

230.

231.

232.

233.

234.

235.

236.

237.

238.

239.

240.

241.

242.

243.

244.

245.

246.

247.

248.

249.

250.

251.

Yu D. The contribution of P-glycoprotein to pharmacokinetic drug interactions. J Clin Pharmacol.

1999;39(12):1203–1211.

Hooymans P, Merkus F. Current status of cardiac glycoside drug interactions. Clin Pharm. 1985;4(4):404–413.

Rodin S, Johnson B. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet. 1988;11(4):227–244.

Fromm MF et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the

interaction between digoxin and quinidine. Circulation. 1999;99(4):552–557.

Boyd RA et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal Pglycoprotein-mediated secretion. J Clin Pharmacol. 2000;40(1):91–98.

Verschraagen M et al. P-glycoprotein system as a determinant of drug interactions. The case of digoxinverapamil. Pharmacol Res. 1999;40(4):301–306.

Tanaka H et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother.

2003;37(2):178–181.

Wakasugi H et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin

Pharmacol Ther. 1998;64(1):123–128.

Johne A et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum

perforatum). Clin Pharmacol Ther. 1999;66(4):338–345.

Kelly R, Smith T. Recognition and management of digitalis toxicity. Am J Cardiol. 1992;69(18):108G–118G; disc

118G–119G.

Bernabei R et al. Digoxin serum concentration measurements in patients with suspected digitalis arrhythmias. J

Cardiovasc Pharmacol. 1980;2(3):319–329.

Reisdorff EJ et al. Acute digitalis poisoning: the role of intravenous magnesium sulfate. J Emerg Med.

1986;4(6):463–469.

Lely AH, van Enter C. Non-cardiac symptoms of digitalis intoxication. Am Heart J. 1972;83(2):149–152.

Butler VP Jr et al. Digitalis induced visual disturbances with therapeutic digitalis concentrations. Ann Intern

Med. 1995;123(9):675–680.

Beller GA et al. Digitalis intoxication: a prospective clinical study with serum level correlations. N Engl J Med.

1971;284(18):989–997.

Lee T, Smith T. Serum digoxin concentration and diagnosis of digitalis toxicity. Clin Pharmacokinet.

1983;8(4):279–285.

Park GD et al. Digoxin toxicity in patients with high serum digoxin concentrations. Am J Med Sci.

1987;30(6):423–428.

Shapiro W. Correlative studies of serum digitalis levels and the arrhythmias of digitalis intoxication. Am J

Cardiol. 1978;41(5):852–859.

Ordog GJ et al. Serum digoxin levels and mortality in 5100 patients. Ann Emerg Med. 1987;16(1):32–39.

Jelliffe RW. Factors to consider in planning digoxin therapy. J Chronic Dis. 1971;24:407.

Antman E et al. Treatment of 150 cases of life threatening digitalis toxicity. Circulation. 1990;81(6):1744–1752.

Woolf AD et al. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J

Med. 1992;326(26):1739–1744.

Borron SW et al. Advances in the management of digoxin toxicity in the older patient. Drugs Aging.

1997;10(1):18–33.

Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific FAB therapy in the management of digitalis

toxicity. Clin Pharmacokinet. 1995;28(6):483–493.

Ujhelyi MR et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and

free digoxin. Ann Intern Med. 1993;119(4):273–277.

Hickey AR et al. Digoxin immune Fab in the management of digitalis intoxication: safety and efficacy results of

an observationalsurveillance study. J Am Coll Cardiol. 1991;17(3):590–598.

Rector TS et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine

plus isosorbide dinitrate on quality of life. V-HeFT II. Circulation. 1993;87(Suppl VI):V171–V177.

Mulrowe J, Crawford M. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart

failure. Clin Pharmacokinet. 1989;16(2):86–89.

Kalus J, NappiJ. Role of race in the pharmacotherapy of heart failure. Ann Pharmacother. 2002;36(3):471–478.

Carson P et al. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart

Failure Trials. J Card Fail. 1999;5(3):178–187.

Shekelle PG et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of

left ventricular systolic dysfunction according to race, gender and diabetic status: a meta-analysis of major

252.

253.

254.

255.

256.

257.

258.

259.

260.

261.

262.

263.

264.

265.

266.

267.

268.

269.

270.

271.

272.

273.

274.

275.

276.

clinical trials. J Am Coll Cardiol. 2003;41(9):1529–1538.

Yancy CW et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart

failure. N EnglJ Med. 2001;344(18):1358–1365.

Curtis LH et al. Early and long-term outcomes of heart failure in elderly persons, 2001–2005. Arch Intern Med.

2008;168(22):2481–2488.

Acute decompensated heart failure national registry. http://www.adhereregistry.com/back.html. Accessed

Janauary 24, 2011.

Nohria A et al. Medical management of advanced heart failure. JAMA. 2002;287(5):628–640.

Grady KL et al. Team management of patients with heart failure: a statement for healthcare professionals from

the Cardiovascular Nursing Council of the American Heart Association. Circulation. 2000;102(19):2443–2456.

Stevenson LW et al. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am

Heart J. 1998;135(6, Pt 2 Su):S293–S309.

Stevenson LW, Perloff JK. The limited reliability of physicalsigns for estimating hemodynamics in chronic heart.